AL
ALDX.US Aldeyra The
- Market cap
- USD 38.9M
- P/E
- -
- P/B
- 1.08x
- ROE
- 0.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ALDX.US undervalued?
Graham numberThe Graham number of Aldeyra The cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aldeyra The fundamental analysis
No fundamental analysis for Aldeyra The yet.
Aldeyra The stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-…
Full company profileAldeyra The financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aldeyra The annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -35.8K | -37.8K | -71.0K | -96.3K | -56.2K | -264K | -259K | -263K | -250K | -252K | - |
| Operating Income | -18.7M | -22.5M | -39.7M | -63.1M | -36.4M | -56.2M | -62.7M | -42.8M | -60.1M | -35.3M | -18.0M |
| EBITDA | -18.6M | -22.2M | -38.7M | -61.4M | -34.3M | -55.8M | -60.1M | -35.2M | -53.7M | -31.7M | -15.9M |
| Net Income | -18.7M | -22.3M | -38.9M | -60.8M | -37.6M | -57.8M | -62.0M | -37.5M | -55.9M | -33.8M | -16.9M |
| EPS | -1.65 | -1.40 | -1.79 | -2.24 | -1.11 | -1.07 | -1.06 | -0.64 | -0.94 | -0.56 | -0.28 |
| Balance Sheet | |||||||||||
| Total Assets | 25.2M | 44.2M | 95.1M | 75.5M | 83.4M | 233M | 181M | 148M | 105M | 72.1M | 43.4T |
| Total Liabilities | 3.54M | 4.57M | 8.47M | 27.4M | 23.8M | 27.4M | 30.3M | 28.5M | 33.6M | 27.8M | 8.16T |
| Shareholders' Equity | 21.6M | 39.6M | 86.6M | 48.1M | 59.5M | 206M | 151M | 120M | 71.0M | 44.3M | 35.2T |
| Cash & Short-term Investments | 24.9M | 42.9M | 93.6M | 73.4M | 77.9M | 230M | 174M | 143M | 101M | 70.0M | 41.0T |
| Total Debt | 1.32M | 1.34M | - | 14.8M | 15.3M | 15.9M | 16.1M | 15.7M | 15.3M | 15.5M | 459B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -15.1M | -19.2M | -29.9M | -45.0M | -37.5M | -42.6M | -56.6M | -30.3M | -43.2M | -33.3M | -18.4M |
| Capital Expenditure | 11.8K | 24.8K | 263K | 9.53K | 5.00 | 7.81K | 16.3K | 2.00 | 0.00 | 0.00 | 61.6K |
| Free Cash Flow | -15.2M | -19.2M | -30.1M | -45.0M | -37.5M | -42.6M | -56.7M | -30.3M | -43.2M | -33.3M | -18.5M |
| Ratios | |||||||||||
| ROE | -86.4% | -56.4% | -44.9% | -126.5% | -63.1% | -28.1% | -41.1% | -31.3% | -78.7% | -76.5% | 0.0% |
| ROA | -74.2% | -50.6% | -40.9% | -80.5% | -45.1% | -24.8% | -34.2% | -25.3% | -53.4% | -47.0% | 0.0% |
| Debt to Equity | 0.06x | 0.03x | - | 0.31x | 0.26x | 0.08x | 0.11x | 0.13x | 0.22x | 0.35x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aldeyra The dividends
Aldeyra The has not paid dividends in the last 9 fiscal years.
Who owns Aldeyra The
- Insiders 3.62%
- Institutions 55.53%
- Public & others 40.85%
- Shares outstanding 60.4M
- Free float 49.0M
Top funds holding ALDX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.78M | 2.96% | 0.00% | Sep 2026 |
| Vanguard Explorer Inv | 332K | 0.55% | 0.00% | Sep 2026 |
| Vanguard VIF Small Co Gr | 308K | 0.51% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 275K | 0.46% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 180K | 0.30% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 168K | 0.28% | +0.12% | Sep 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 103K | 0.17% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 85.4K | 0.14% | 0.00% | Sep 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 79.5K | 0.13% | +1.92% | Oct 2026 |
| Fidelity Series Total Market Index | 72.7K | 0.12% | 0.00% | Sep 2026 |
| AlphaCentric Life Sciences & Hlthcare I | 37.7K | 0.06% | +1.44% | Jun 2026 |
| T. Rowe Price Extended Equity Market Idx | 35.1K | 0.06% | 0.00% | Sep 2026 |
| Mackenzie GQE US Small Cap F8 | 35.1K | 0.06% | 0.00% | Aug 2026 |
| Vanguard Balanced Index Inv | 34.7K | 0.06% | 0.00% | Sep 2026 |
| Dimensional US Small Cap ETF | 28.1K | 0.05% | 0.00% | Oct 2026 |
| Fidelity ZERO Total Market Index | 27.3K | 0.05% | 0.00% | Sep 2026 |
| Russell Inv US Small Cap Equity Y | 20.3K | 0.03% | +20.58% | Sep 2026 |
| Fidelity ZERO Extended Market Index | 19.2K | 0.03% | -41.38% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 17.7K | 0.03% | 0.00% | Sep 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 14.5K | 0.02% | +156.45% | Jun 2026 |
Top institutions holding ALDX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Knoll Capital Management LP | 5.48M | 9.07% | 0.00% | Jun 2026 |
| AQR Capital Management LLC | 3.75M | 6.22% | +32.57% | Jun 2026 |
| Kingdon Capital Management LLC | 2.65M | 4.39% | +23.23% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.36M | 3.91% | -0.08% | Jun 2026 |
| D. E. Shaw & Co LP | 1.94M | 3.21% | +38.20% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 1.51M | 2.50% | +1,061.95% | Jun 2026 |
| Jane Street Group LLC | 1.38M | 2.28% | +41.93% | Jun 2026 |
| BlackRock Inc | 1.26M | 2.08% | -66.60% | Jun 2026 |
| Qube Research & Technologies | 1.13M | 1.87% | +1,196.31% | Jun 2026 |
| Acadian Asset Management LLC | 1.06M | 1.76% | +23.94% | Jun 2026 |
| Ardsley Advisory Partners | 975K | 1.62% | +2.63% | Jun 2026 |
| Renaissance Technologies Corp | 882K | 1.46% | +2.18% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 795K | 1.32% | -1.60% | Jun 2026 |
| The Goldman Sachs Group Inc | 725K | 1.20% | +33.56% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 647K | 1.07% | -18.82% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 608K | 1.01% | +17.29% | Jun 2026 |
| Geode Capital Management, LLC | 596K | 0.99% | -52.38% | Jun 2026 |
| GSA Capital Partners LLP | 473K | 0.78% | +91.17% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 421K | 0.70% | 0.00% | Jun 2026 |
| CANTOR FITZGERALD, L. P. | 400K | 0.66% | 0.00% | Jun 2026 |
Aldeyra The company profile
- Company name
- Aldeyra The
- Ticker
- ALDX.US
- Exchange
- USA Stocks
- Listed since
- May 2, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Fiscal year end
- December
- Address
- 131 Hartwell Avenue, Lexington, MA, United States, 02421
- Phone
- 781 761 4904
- Website
- aldeyra.com
About Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Aldeyra The management
4- Dr. Todd C. Brady M.D., Ph.D.CEO, President & Director · born 1972
- Mr. Michael AlfieriHead of Finance and Principal Financial & Accounting Officer · born 1965
- David BurkeHead of Investor Relations
- Dr. Adam LazorchakDirector of Translational Sciences & Non-Clinical Development